MILNE GEORGE M JR
MILNE GEORGE M JR's purchase track record
How the stock did after each of MILNE GEORGE M JR's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/3/2024 | AMLX | $220K | +147.7% | +39.4% | +4.5% |
| 3/2/2023 | AUPH | $178K | +2.0% | +1.5% | +13.2% |
| 3/4/2022 | AUPH | $54K | +7.6% | -31.8% | -9.3% |
| 1/6/2022 | AMLX | $500K | -21.4% | +21.8% | -16.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
AUPH Appears in Report on Activist Investor Activity. Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.
Transaction History
| AMLX | ▼ Sell | Gift | 17,780 | $0 | 1/12/2026 | View on chart |
| AMLX | ▼ Sell | Gift | 27,910 | $0 | 1/24/2025 | View on chart |
| AMLX | ▲ Buy | Open Market | 100,000 | $220K | 9/3/2024 | View on chart |
| AMLX | ▼ Sell | Gift | 9,100 | $0 | 1/25/2024 | View on chart |
| AMLX | ▼ Sell | Gift | 94,350 | $0 | 1/16/2024 | View on chart |
| AUPH | ▲ Buy | Option Exercise | 8,733 | — | 5/18/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 33,084 | $1.1M | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,916 | $62K | 3/16/2023 | View on chart |
| AUPH | ▲ Buy | Open Market | 20,000 | $178K | 3/2/2023 | View on chart |
| AUPH | ▲ Buy | Open Market | 5,000 | $54K | 3/4/2022 | View on chart |
| AMLX | ▲ Buy | Open Market | 26,315 | $500K | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.